Please assess the completion status of the following clinical trial:

Trial Title: Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged ≥55 years old~* With newly diagnosed ALL without prior treatment~* Capable to receive polychemotherapy (World Health Organization (WHO) performance status ≤2)~* With or without meningeal disease~* Having signed an Informed Consent Form~* Subscribed to social security insurance~Exclusion Criteria:~* ALL translocation(9;22) and/or BCR-ABL (Breakpoint Cluster Region-Abelson) positive~* Performance status incompatible with chemotherapy treatment (WHO score \>2)~* Patient presenting with a general or visceral contraindication to intensive treatment including :~  * Cardiac insufficiency defined as Left Ventricular Ejection Fraction \<50% of the theoretical value~ * Plasma creatinine concentration 2 times greater than the upper limit of laboratory ranges, except if related to ALL~ * Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) levels 5 times greater than the upper limit of laboratory ranges, except if related to ALL~ * Patient with another evolutive cancer other than ALL~ * Severe evolutive infection, or Human Immunodeficiency Virus (HIV) seropositive or, active hepatitis related to B or C viral infection~* Prior treatment with L-asparaginase (irrespective of the form)~* History of grade 3 transfusional incident (life threatening)~* Patient presenting rare and/or dangerous anti-erythrocyte antibodies thus leading to the unavailability of phenotype compatible Red Blood Cells Concentrate~* Patient included in another clinical trial during the last 4 weeks

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GRASPA 50 IU/kg (Type: EXPERIMENTAL): Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
- GRASPA 100 IU/kg (Type: EXPERIMENTAL): Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
- GRASPA 150 IU/kg (Type: EXPERIMENTAL): Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase

Based on this trial design, predict the completion outcome and termination type (if applicable).